Biomarkers in Thoracic Aorta Surgery
Role of Intraoperative Biomarkers in Prognosis of Perioperative Complications in Reconstructive Thoracic Aorta Surgery
1 other identifier
interventional
132
1 country
1
Brief Summary
Biomarkers can play a vital role in prognosing the perioperative complications in thoracic aorta surgery. The goal of a study is to determine the correlation between intraoperative level of certain biomarkers and total amount of peroperative complications.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 22, 2020
CompletedFirst Posted
Study publicly available on registry
December 30, 2020
CompletedStudy Start
First participant enrolled
March 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2022
CompletedResults Posted
Study results publicly available
May 6, 2024
CompletedSeptember 19, 2024
August 1, 2024
11 months
December 22, 2020
November 23, 2023
August 23, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Number of Total Postoperative Complications
Value reported in the Outcome Measure data table reflects the Number of Total Postoperative Complications across all participants.
up to 10 days
Secondary Outcomes (5)
Total Number Affected by All-Cause Mortality
up to 10 days
Number of Participants Who Require Extracorporeal Detoxication
up to 10 days
Number of Cardiac Disorders
up to 10 days
Number of Vascular Disorders
up to 10 days
Number of Infections and Infestations
up to 10 days
Study Arms (1)
Thoracic aorta surgery patients
EXPERIMENTALBlood samples on proadrenomedullin, presepsin, NT-proBNP, Troponin I, procalcitonin are acquired
Interventions
Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
Eligibility Criteria
You may qualify if:
- Elective thoracic and thoracoabdominal surgery
You may not qualify if:
- Hemolysis in blood sample
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Petrovsky Research National Centre of Surgery ( Petrovsky NRCS)
Moscow, 119991, Russia
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Artem Gubko
- Organization
- Petrovsky NRCS
Study Officials
- STUDY DIRECTOR
Boris Akselrod, Professor
Petrovsky NRCS
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 22, 2020
First Posted
December 30, 2020
Study Start
March 1, 2021
Primary Completion
February 1, 2022
Study Completion
May 1, 2022
Last Updated
September 19, 2024
Results First Posted
May 6, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share